Perjeta Among Biosimilar Targets As Viatris Insists It Can ‘Do A Lot More’

Viatris Has Identified 13 New Biosimilar Targets For Development

 
• By Dean Rudge

At Viatris’ inaugural investor day, management spoke at length about the company’s ambitions for biosimilars, underlining that the company currently had no plans to expand its manufacturing footprint at the present time.

Watering_Plant
Viatris has approximately 150 biosimilar marketing authorizations in over 85 countries • Source: Shutterstock

More from Biosimilars

More from Products